Other Events ·
Jury awards Nektar $90 million plus interest against Eli Lilly for breaching license agreement
NKTRNektar Therapeutics
On September 24, 2026, a jury in the U.S. District Court for the Northern District of California found Eli Lilly and Company liable for breaching the implied covenant of good faith and fair dealing under their license agreement for rezpegaldesleukin. The jury awarded Nektar Therapeutics $90 million in damages plus interest to be determined by the court. This verdict is subject to post-trial proceedings and potential appeal. Nektar Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.